Back to Search
Start Over
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1.
- Source :
-
Leukemia [Leukemia] 2024 Aug; Vol. 38 (8), pp. 1843-1847. Date of Electronic Publication: 2024 May 15. - Publication Year :
- 2024
- Subjects :
- Humans
Protein Kinase Inhibitors therapeutic use
Protein Kinase Inhibitors pharmacology
Fusion Proteins, bcr-abl genetics
Fusion Proteins, bcr-abl antagonists & inhibitors
Drug Resistance, Neoplasm genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics
Drug Repositioning methods
Subjects
Details
- Language :
- English
- ISSN :
- 1476-5551
- Volume :
- 38
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Leukemia
- Publication Type :
- Editorial & Opinion
- Accession number :
- 38750137
- Full Text :
- https://doi.org/10.1038/s41375-024-02282-y